NEW YORK (360Dx) – Progentec Diagnostics is developing a protein biomarker platform and assay that's showing promise in predicting lupus flares, which are painful for patients and can occur without warning or a clear cause.

The firm's chances of reaching commercialization and achieving adoption have been improved by its signing of strategic investor Mayo Clinic Ventures, an organization with a cadre of physicians that could benefit from use of the test, Scott Meacham, CEO of non-profit investment funding firm i2E and an investor in Progentec, said in an interview.